Denovicon is Accepted into the 3DEXPERIENCE Lab Accelerator

On October 21, 2024, Denovicon Therapeutics was officially accepted into the 3DEXPERIENCE Lab accelerator. “I am very pleased to welcome Denovicon Therapeutics to drive this [revolution in drug discovery] effort and bring something really disruptive in this domain,” said Frederic Vacher, Head of Innovation at Dassault Systèmes. Jason Benedict of BIOVIA also expressed his enthusiasm, “We’ve worked with [Denovicon] for some time on many topics. I’m excited for this collaboration through our 3DEXPERIENCE Lab and look forward to seeing Denovicon Therapeutics breakthrough discoveries.” You can learn more about the Denovicon–3DEXPERIENCE Lab collaboration here.